Crestor (Rosuvastatin) Cost in North Dakota: 2026 Prices, Insurance, and Savings

What Rosuvastatin Actually Costs in North Dakota in 2026

The price gap between brand-name Crestor and its generic equivalent is enormous in North Dakota. AstraZeneca lists Crestor at approximately $290 per month for a 30-day supply, a figure that has remained relatively stable since 2024. Generic rosuvastatin, by contrast, averages about $15 per month at retail pharmacies across the state.

Brand vs. Generic Pricing Breakdown

That $275 monthly difference adds up to $3,300 per year. For a drug most patients take indefinitely, the lifetime cost implications are significant. The FDA-approved prescribing information for Crestor lists identical active ingredient specifications for generic rosuvastatin calcium tablets, meaning therapeutic equivalence is established at the regulatory level.

Why Cash Prices Vary Between Pharmacies

Cash-pay pricing in North Dakota fluctuates between $8 and $25 depending on the pharmacy, the manufacturer, and the dose strength. Rural pharmacies in western North Dakota (Williston, Dickinson, Watford City) sometimes price 10%, 20% higher than Fargo or Bismarck locations due to lower prescription volume and higher distribution costs. Patients filling at Walmart, Costco, or mail-order pharmacies tend to pay at or below the $15 state average.

The 40 mg Dose Exception

One pricing wrinkle: the 40 mg tablet often costs more per unit than lower strengths. Patients on 40 mg rosuvastatin may find their monthly cash cost closer to $20, $28. This matters because the JUPITER trial (N=17,802) used rosuvastatin 20 mg daily and demonstrated a 44% reduction in the primary cardiovascular endpoint [1]. Most patients reach their LDL-C target at 10 mg or 20 mg, so the 40 mg price premium affects a smaller subset.

North Dakota Medicaid and Rosuvastatin Coverage

North Dakota Medicaid does not cover Crestor as of 2026. This affects roughly 90,000 Medicaid enrollees statewide. The state's preferred drug list includes alternative statins (atorvastatin, simvastatin, pravastatin) but excludes both brand Crestor and generic rosuvastatin from standard formulary coverage.

What Medicaid Patients Can Do

Patients who need rosuvastatin specifically (for example, those with documented intolerance to atorvastatin or those who require rosuvastatin's particular pharmacokinetic profile for renal dosing) can request a prior authorization. The North Dakota Department of Health and Human Services processes prior authorization requests through its pharmacy benefits manager, and approvals typically require documentation of therapeutic failure on at least one preferred statin.

Clinical Rationale for Rosuvastatin-Specific Requests

Rosuvastatin has the highest LDL-C reduction potency per milligram among available statins. According to the 2018 AHA/ACC Cholesterol Clinical Practice Guideline, high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) is recommended for patients with clinical atherosclerotic cardiovascular disease [2]. For patients who experience myalgia on atorvastatin 80 mg, rosuvastatin 20 mg offers an evidence-based alternative that can achieve comparable LDL-C lowering with a different side-effect profile.

A 2016 Cochrane systematic review of rosuvastatin for cardiovascular disease prevention found that rosuvastatin reduced major cardiovascular events in primary prevention populations, with an NNT of approximately 62 over 2 years for composite cardiovascular events in the JUPITER population [3]. That Cochrane analysis is available through the Cochrane Library.

Insurance Coverage Beyond Medicaid

Most commercial insurance plans operating in North Dakota cover generic rosuvastatin on Tier 1 or Tier 2 formularies. Brand Crestor, when covered at all, sits on Tier 3 (preferred brand) or higher, carrying copays of $40, $80 per month.

Major Carriers and Their Formulary Positions

Blue Cross Blue Shield of North Dakota, the state's largest commercial insurer, lists generic rosuvastatin as a preferred generic with copays typically between $5 and $15. Sanford Health Plan and Medica, which serve large portions of the Fargo-Moorhead and Grand Forks markets, similarly place generic rosuvastatin on preferred tiers. For patients enrolled in employer-sponsored plans administered by UnitedHealthcare or Cigna, generic rosuvastatin copays generally fall below $10.

Medicare Part D in North Dakota

Medicare Part D plans available during the 2026 enrollment period overwhelmingly cover generic rosuvastatin. Among the 30+ Part D plans offered in North Dakota, nearly all place generic rosuvastatin on Tier 1. Beneficiaries in the coverage gap (the "donut hole") pay 25% coinsurance, which on a $15 drug translates to under $4 per month. Brand Crestor, if prescribed, falls under the brand-name discount program in the gap but still costs substantially more out of pocket.

Self-Pay vs. Insured: When Cash Pay Wins

Here is a situation many North Dakota patients encounter: their insurance copay for generic rosuvastatin is $15, and the cash price at a nearby pharmacy is also $15. In these cases, paying cash and using a manufacturer or pharmacy discount card may actually yield a lower effective price ($8, $12) than routing the claim through insurance. Patients should compare both options at the pharmacy counter before assuming insurance is the better deal.

Compounded Rosuvastatin in North Dakota

Compounded rosuvastatin is available in North Dakota through 503A-licensed compounding pharmacies. Under federal law (the Drug Quality and Security Act of 2013), 503A pharmacies may compound patient-specific prescriptions when a prescriber determines a clinical need.

Who Benefits from Compounded Formulations

Compounded rosuvastatin serves a narrow but real clinical niche. Patients who cannot swallow tablets (post-stroke dysphagia, for example), patients who need a dose not commercially available (such as 7.5 mg), or patients with excipient sensitivities may benefit from compounded preparations. The compounded product is prepared per individual prescription and is not interchangeable with the FDA-approved generic.

Cost and Regulatory Considerations

Compounded rosuvastatin cost varies by pharmacy, but some 503A facilities in North Dakota advertise prices near $0 for basic formulations (before dispensing fees). Patients should verify that any compounding pharmacy they use holds a valid North Dakota Board of Pharmacy license and operates under 503A (patient-specific) or 503B (outsourcing facility) designation. The FDA's compounding page provides current guidance on the regulatory framework.

Telehealth Prescribing of Rosuvastatin in North Dakota

North Dakota permits telehealth prescribing for rosuvastatin. A prescriber licensed in North Dakota can evaluate a patient via audio-video visit, review lipid panel results, and electronically prescribe rosuvastatin to any North Dakota pharmacy.

How the Process Works

The typical telehealth workflow looks like this: a patient completes an intake form and uploads recent lab results (lipid panel within the past 12 months), a licensed provider reviews the data and conducts a synchronous video consultation, and the prescription is sent to the patient's preferred pharmacy. Turnaround from consultation to filled prescription is often 24 to 48 hours.

Lab Requirements Before Starting Therapy

Before initiating statin therapy, the 2018 AHA/ACC guideline recommends a fasting lipid panel, along with assessment of 10-year ASCVD risk using the Pooled Cohort Equations [2]. For patients aged 40 to 75 with LDL-C between 70 and 189 mg/dL and a 10-year ASCVD risk of 7.5% or higher, the guideline recommends moderate-to-high-intensity statin therapy. Rosuvastatin 10 mg qualifies as moderate intensity. Rosuvastatin 20 mg or 40 mg qualifies as high intensity.

Monitoring After Initiation

Follow-up labs are recommended 4 to 12 weeks after starting rosuvastatin, then every 3 to 12 months thereafter. A hepatic function panel at baseline is standard practice, and the prescribing label recommends checking CK levels only if the patient reports muscle symptoms. The JUPITER trial measured hsCRP in addition to LDL-C and found that rosuvastatin 20 mg reduced median hsCRP by 37% at 12 months [1].

Discount Programs and Savings Strategies

Several pathways exist for reducing rosuvastatin costs in North Dakota, even beyond the already-low generic price.

AstraZeneca Savings Card

AstraZeneca offers a manufacturer savings card for brand Crestor that can reduce copays for commercially insured patients. The card typically brings the out-of-pocket cost to $3, $30 per fill for eligible patients. Patients with government insurance (Medicare, Medicaid, Tricare) are not eligible for the savings card under federal anti-kickback statute restrictions.

Pharmacy Discount Programs

Walmart's $4 generic list includes rosuvastatin at some dose strengths. Costco's member pricing frequently undercuts other retail pharmacies by 20%, 40%. GoodRx, RxSaver, and similar discount platforms show North Dakota rosuvastatin prices as low as $8 per 30-day supply at select pharmacies. These are not insurance; they are negotiated cash-price discounts.

90-Day Supply Savings

Filling a 90-day supply instead of three consecutive 30-day fills saves $5, $15 per quarter at most North Dakota pharmacies. Mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) often offer 90-day generic supplies at the cost of two monthly copays, effectively giving patients a 33% discount.

Patient Assistance Programs

For uninsured patients whose income falls below 200%, 300% of the federal poverty level, several patient assistance programs cover rosuvastatin at no cost. NeedyMeds and RxAssist maintain updated directories of these programs. AstraZeneca's own patient assistance program covers brand Crestor for qualifying individuals, though generic availability makes this less commonly utilized than it was before 2016.

Clinical Context: Why Rosuvastatin Pricing Matters for ASCVD Prevention

The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) randomized 17,802 apparently healthy men and women with LDL-C <130 mg/dL and hsCRP ≥2 mg/L to rosuvastatin 20 mg daily versus placebo [1]. The trial was stopped early at a median follow-up of 1.9 years because of a 44% relative reduction in the primary composite endpoint (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death). Absolute risk reduction was 1.2 percentage points, yielding an NNT of 83 over 1.9 years.

Dr. Paul Ridker, lead investigator of JUPITER, stated: "These data indicate that apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein benefit from statin treatment" [1]. That finding expanded the clinical population for whom statin therapy could be considered, and it has direct implications for North Dakota, where cardiovascular disease is the leading cause of death according to the CDC [4].

A 2010 meta-analysis published in The Lancet, the Cholesterol Treatment Trialists' (CTT) Collaboration, examined individual patient data from 170,000 participants across 26 randomized trials [5]. The CTT analysis found that each 1 mmol/L (approximately 39 mg/dL) reduction in LDL-C produced a 22% proportional reduction in major vascular events over 5 years (Lancet 2010). Rosuvastatin 10 mg reduces LDL-C by approximately 46%, and rosuvastatin 20 mg by approximately 52%, based on FDA label data.

At $15 per month ($180 per year), generic rosuvastatin in North Dakota represents one of the most cost-effective cardiovascular risk reduction strategies available. The World Health Organization includes statins on its Model List of Essential Medicines [6], reflecting their global public health significance.

North Dakota-Specific Pharmacy Field

North Dakota has a unique pharmacy regulatory environment. It is the only U.S. State that restricts pharmacy ownership to licensed pharmacists (N.D.C.C. § 43-15-35), meaning chain pharmacy corporations cannot own pharmacies outright. This creates a market dominated by independent pharmacies and pharmacist-owned chains.

How Ownership Laws Affect Pricing

The practical effect on rosuvastatin pricing is mixed. Independent pharmacies may have less purchasing power than national chains, but they also have more flexibility to set competitive cash prices and to engage in direct contracting with generic manufacturers. Patients in Fargo and Bismarck report rosuvastatin cash prices comparable to or slightly above national averages, while patients in smaller communities sometimes find modestly higher prices.

Pharmacy Access in Rural Areas

North Dakota's population density (11.5 people per square mile) means some residents drive 30+ miles to the nearest pharmacy. This is where mail-order pharmacy and telehealth prescribing converge: a patient in rural McKenzie County can see a provider via video, receive an electronic prescription, and have a 90-day supply of rosuvastatin delivered by mail, never leaving home.